| Engerix-B (hepatitis B vaccine recombinant) / GSK |
NCT00699231: Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients |
|
|
| Completed | 1 | 30 | Europe | HBV-MPL vaccine 208129, Engerix™-B | GlaxoSmithKline | Hepatitis B | 12/92 | 12/92 | | |
NCT00354861: A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321 |
|
|
| Completed | 1 | 48 | Europe | hepatitis B antigen (without alum) plus IMP321, CD223, hLAG-3Ig, LAG-3, hepatitis B antigen alone (without alum), Engerix B | Immutep S.A.S., SGS Aster-Cephac (CRO) | Healthy | 11/05 | 02/06 | | |
NCT00426712: Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients |
|
|
| Completed | 1 | 42 | US | 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, HEPLISAV™, Hepatitis B Vaccine (Recombinant), ENGERIX-B® | Dynavax Technologies Corporation | Hepatitis B | 03/08 | 03/08 | | |
NCT01817725: Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg |
|
|
| Completed | 1 | 20 | RoW | HBV vaccine (Engerix B) | Chang Gung Memorial Hospital | Chronic Hepatitis B | 02/16 | 02/16 | | |
